New drug formula offers COPD hope

People suffering with chronic obstructive pulmonary disease (COPD) could soon receive a treatment, following positive trials of a drug comprising tiotropium and olodateral. The TONADO study on tiotropium and olodateral (Respimat) looked at the experiences of more than 5,000 people living with COPD and found the drug provided increased lung function and improved quality of life compared to either compound alone. The results, presented at this year’s European Respiratory Society International Congress 2014 in Munich, verified similar results presented in the VIVACITO study presented earlier this year.  Currently tiotropium (Spiriva) is the most prescribed treatment for COPD. Olodateral was specifically